Newark, DE – According to filings with the U.S. Securities and Exchange Commission, Virion Therapeutics is raising $6,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Bernard Rudnick played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Virion Therapeutics

Founded in early 2018 to advance technology licensed from The Wistar Institute, an international leader in biomedical research with special expertise in vaccine, cancer and infectious disease research, Virion has built an experienced biotechnology management team, augmented by its advisory board that has extensive domain knowledge in antiviral, vaccine and oncology therapeutic arenas. Virion’s initial development programs are targeted for treatment of human papillomavirus-induced cancers and chronic hepatitis B virus infections.

To learn more about Virion Therapeutics, visit http://www.viriontx.com/

Contact:
Bernard Rudnick, Chief Executive Officer
800-841-9303
brudnick@viriontx.com
https://www.linkedin.com/in/bernie-rudnick-5334a815/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved